In one paragraphArticle in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors.
Barbara T BezerraInstituto Carlos Chagas, Fundação Oswaldo Cruz (Fiocruz), Curitiba, Brazil.
Daniel A MellonInstituto Carlos Chagas, Fundação Oswaldo Cruz (Fiocruz), Curitiba, Brazil.
Cássia M SouzaInstituto Carlos Chagas, Fundação Oswaldo Cruz (Fiocruz), Curitiba, Brazil.
Rafael F CastelliInstituto Carlos Chagas, Fundação Oswaldo Cruz (Fiocruz), Curitiba, Brazil.
Amanda C Camillo-AndradeInstituto Carlos Chagas, Fundação Oswaldo Cruz (Fiocruz), Curitiba, Brazil.
Marlon D M SantosInstituto Carlos Chagas, Fundação Oswaldo Cruz (Fiocruz), Curitiba, Brazil.
Haroldo C de OliveiraDepartment of Microbiology, Immunology, and Parasitology, Discipline of Cellular Biology, Federal University of Sao Paulo (UNIFESP), Sao Paulo, Brazil.ORCID 0000-0001-5760-4209 Funding
An extracellular vesicle component as a candidate to control cryptococcosis.R01AI183314 · NIAID · FUNDACAO OSWALDO CRUZ · PI JOSHUA D NOSANCHUK, Marcio Lourenco Rodrigues · 2024 to 2026
$380kConselho Nacional de Desenvolvimento Científico e Tecnológico 304998/2022-2Conselho Nacional de Desenvolvimento Científico e Tecnológico 402651/2024-3Conselho Nacional de Desenvolvimento Científico e Tecnológico 404365/2023-0Conselho Nacional de Desenvolvimento Científico e Tecnológico 406639/2025-6FOCEM-COF 03/11Fundação de Amparo à Pesquisa do Estado de São Paulo 2025/08729-7Global AMR Innovation Fund (GAMRIF) initiative FR1-49NAPI Protemica from Araucaria Foundation 2013; Parana 442655/2023-1National Institute of Allergy and Infectious Diseases R01AI183314NIAID NIH HHS R01 AI183314Program for Research Stimulation (PEP) of the Carlos Chagas Institute of Fiocruz PEP
6 · The paper itselfAbstract
Cryptococcosis is a systemic mycosis caused by
Indexed as
Antifungal AgentsCryptococcosisCryptococcusCryptococcus neoformansAmphotericin BAnimalsBiofilmsDrug SynergismMacrophagesMiceMicrobial Sensitivity TestsAmphotericin BAntifungal Agentsantifungal activityantifungal drugs synergismbiofilmbrilacidincryptococcosisCryptococcus deuterogattiiCryptococcus neoformansproteomics
Identifiers
PMID42294727
PMCPMC13340292
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390